摘要
目的 对并发肾性贫血的维持性血液透析患者实施左卡尼汀、重组人促红素结合疗法的治疗疗效展开分析.方法 此次研究对象是62例并发肾性贫血的维持性血液透析患者,均选取自2023年1月-2024年3月期间,根据数字表随机分组原则将研究对象划分为两组,31例患者为一组,两组患者均行常规治疗,以此为先决条件,将联合实施重组人促红素疗法的组别设为比对组,将联合实施重组人促红素+左卡尼汀疗法的组别设为讨论组,对两组治疗效果进行讨论评析,观察的指标分别是炎症因子水平、贫血改善效果、治疗疗效、药物不良反应.结果 讨论组患者于疗程结束时,其炎症因子水平检测结果均低于比对组,组间差异显著(P<0.05);讨论组患者疗程结束时的贫血检测指标均高于比对组,组间差异显著(P<0.05);讨论组患者的临床治疗总疗效较比对组总疗效高,组间差异显著(P<0.05);讨论组患者用药期间的药物不良反应总发生率明显低于比对组,组间差异显著(P<0.05).结论 维持性血液透析患者并发肾性贫血后,实施常规治疗的同时,再联合重组人促红素、左卡尼汀药物方案,可以迅速减轻患者体内炎症反应,改善肾性贫血病情,是疗效确切、安全性高的联合用药方案.
Objective To discuss and evaluate the therapeutic effect of L-carnitine combined with recombinant human erythropoietin on maintenance hemodialysis patients complicated with renal anemia.Methods Sixty-two maintenance hemodialysis patients with renal anemia were randomly divided into two groups from January 2023 to March 2024,thirty-one patients were divided into two groups.The patients in both groups were treated with conventional therapy,the therapeutic effect of recombinant human erythropoietin was evaluated in the control group,on this basis combined with I-carnitine was evaluated in the discussion group,the levels of inflammatory factors,anemia improvement,therapeutic efficacy and adverse drug reactions were observed.Results At the end of treatment,the levels of inflammatory factors in the study group were lower than those in the control group(P<0.05),and the indexes of anemia at the end of treatment in the study group were higher than those in the control group(P<0.05),compared with the control group,the total clinical efficacy of the patients in the discussion group was higher(P<0.05),and the total incidence of adverse drug reactions in the discussion group was significantly lower than that in the control group(P<0.05).Conclusion In maintenance hemodialysis patients with renal anemia,routine treatment combined with recombinant human erythropoietin and 1-carnitine can rapidly reduce the inflammatory reaction in vivo,to improve the condition of renal anemia is an effective and safe combination regimen.
作者
徐克强
Xu Keqiang(Meili People's Hospital,Suzhou,Jiangsu 215500,China)
出处
《首都食品与医药》
2024年第17期72-75,共4页
Capital Food Medicine
关键词
不良反应
左卡尼汀
肾性贫血
炎症
维持性血液透析
adverse reactions
levocarnitine
renal anemia
inflammation
maintenance hemodialysis
